- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00303758
Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating metastatic pancreatic cancer.
PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with metastatic pancreatic cancer that cannot be removed by surgery.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
Primary
- Compare the overall survival of patients with unresectable metastatic pancreatic cancer treated with fluorouracil, leucovorin calcium, and cisplatin followed by gemcitabine hydrochloride vs gemcitabine hydrochloride followed by fluorouracil, leucovorin calcium, and cisplatin.
Secondary
- Compare progression-free survival of patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
- Compare the quality of life of patients treated with these regimens.
- Compare the percentage of these patients needing second-line therapy.
- Compare the duration of hospitalization of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to ECOG performance status (0 or 1 vs 2), participating center, location of the tumor (ampullar region vs other locations), and infusion rate of gemcitabine hydrochloride (30 vs 100 minutes). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive leucovorin calcium IV over 2 hours on day 1, cisplatin IV over 1 hour on day 1 or 2, and fluorouracil IV over 46 hours on day 1 and 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression also receive gemcitabine hydrochloride IV over 30 or 100 minutes weekly for 7 weeks. Patients then receive gemcitabine hydrochloride IV on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive gemcitabine hydrochloride IV over 30 or 100 minutes weekly for 7 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression receive fluorouracil, leucovorin calcium, and cisplatin as in arm I.
Quality of life is assessed at baseline and then every 2 months.
After completion of study therapy, patients are followed periodically for 2 years.
PROJECTED ACCRUAL: A total of 202 patients will be accrued for this study.
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Abbeville, Frankrike, 80101
- Centre Hospitalier d'Abbeville
-
Avignon, Frankrike, 84902
- Hopital Duffaut
-
Blois, Frankrike, 41016
- Centre Hospitalier de Blois
-
Boulogne, Frankrike, F-92104
- Centre Hospitalier Universitaire Ambroise Pare - Boulogne
-
Boulogne Sur Mer, Frankrike, 62200
- Centre Hospitalier Docteur Duchenne
-
Bourg En Bresse, Frankrike, 01012
- C.H. Bourg En Bresse
-
Bourgoin-Jallieu, Frankrike, 38300
- Centre hospitalier Pierre Oudot
-
Caen, Frankrike, 14076
- Centre Hospitalier Universitaire d'Amiens
-
Chalons-en-Champagne, Frankrike, 51000
- Centre Hospitalier de Chalons-en-Champagne
-
Clermont-Ferrand, Frankrike, 63003
- CHR Clermont Ferrand, Hotel Dieu
-
Clichy, Frankrike, 92118
- Hopital Beaujon
-
Colmar, Frankrike, 68024
- Hopital Louis Pasteur
-
Dijon, Frankrike, 21034
- Hopital Du Bocage
-
Dijon, Frankrike, 21079
- Centre de Lutte Contre le Cancer Georges-Francois Leclerc
-
Draguignan, Frankrike, 83300
- Centre Hospitalier Draguignan
-
Dunkerque, Frankrike, 59240
- Centre Hospitalier De Dunkerque - CHD
-
Elbeuf, Frankrike, 76503
- Centre Hospitalier Intercommunal St. Aubin les Elbeuf
-
Grenoble, Frankrike, 38043
- CHU de Grenoble - Hopital de la Tronche
-
Guilherand Granges, Frankrike, 07500
- Clinique Pasteur
-
Libourne, Frankrike, 33500
- Hôpital Robert Boulin
-
Lille, Frankrike, 59037
- Centre Hospital Universitaire Hop Huriez
-
Lille, Frankrike, 59037
- Centre Hospitalier Regional et Universitaire de Lille
-
Lyon, Frankrike, 69437
- Hôpital Edouard Herriot
-
Marseille, Frankrike, 13385
- CHU de la Timone
-
Marseille, Frankrike, 13915
- CHU Nord
-
Marseille, Frankrike, 13008
- Hôpital Saint Joseph
-
Martigues, Frankrike, 13698
- Centre Hospitalier de Martigues
-
Mont-de-Marsan, Frankrike, 40000
- Centre Hospitalier General de Mont de Marsan
-
Montpellier, Frankrike, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Nantes, Frankrike, 44093
- CHR Hotel Dieu
-
Orleans, Frankrike, 45100
- CHR D'Orleans - Hopital de la Source
-
Paris, Frankrike, 75015
- Hopital Europeen Georges Pompidou
-
Paris, Frankrike, 75018
- Hôpital Bichat - Claude Bernard
-
Pessac, Frankrike, 33604
- Hopital Haut Leveque
-
Pontoise, Frankrike, 95301
- Clinique Ste - Marie
-
Reims, Frankrike, 51092
- CHU - Robert Debre
-
Rennes, Frankrike, 35064
- Centre Eugène Marquis
-
Rouen, Frankrike, 76031
- Hopital Charles Nicolle
-
Saint Brieuc, Frankrike, F-22015
- Clinique Armoricaine de Radiologie
-
Saint Martin Boulogne, Frankrike, 62280
- Centre Joliot Curie Des Docteurs Jean-Christophe Chardon Jacques Hernandez Et Laurent Gasnault
-
Saint-Quentin, Frankrike, 02321
- Centre Hospitalier de Saint-Quentin
-
Semur en Auxois, Frankrike, 21140
- Centre Hospitalier de Semur en Auxois
-
Soissons cedex, Frankrike, 02209
- Centre Hospitalier de Soissons
-
Strasbourg, Frankrike, 67098
- Hopital Universitaire Hautepierre
-
Tarbes, Frankrike, 65013
- Centre hospitalier de Tarbes
-
Valence, Frankrike, 26000
- Nouvelle Clinique Generale
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed adenocarcinoma of the pancreas or ampulla
- Metastatic disease
- Unresectable disease
Measurable disease, meeting the following criteria:
- No prior radiotherapy to the only site of measurable disease
- Diameter > 10 mm by spiral CT scan or MRI OR > 20 mm by conventional methods
- No brain metastases
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy > 2 months
- No contraindication to chemotherapy
- Creatinine clearance > 60 mL/min
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Alkaline phosphatase < 5 times normal
- Bilirubin ≤ 3 mg/dL
- No coronary insufficiency
- No symptomatic cardiac disease
- Good hydration possible
- No Child-Pugh class B or C cirrhosis
- No other malignancy except for basal cell skin cancer or carcinoma in situ of the cervix
- Not pregnant or nursing
- Negative pregnancy test
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior palliative or adjuvant chemotherapy
- At least 4 weeks since prior radiotherapy
- No radiotherapy during or for 4 weeks after study therapy
- No other concurrent anticancer therapy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: LV5FU2 simplifié + cisplatine puis gemcitabine si progression
|
|
Eksperimentell: gemcitabine puis LV5FU2 simplifié + cisplatine si progression
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Total overlevelse
Tidsramme: 2012
|
2012
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Giftighet
Tidsramme: 2012
|
2012
|
Progression-free survival
Tidsramme: 2012
|
2012
|
Quality of life
Tidsramme: 2012
|
2012
|
Percentage of patients needing second-line therapy
Tidsramme: 2012
|
2012
|
Duration of hospitalization
Tidsramme: 2012
|
2012
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Jean-Francois Seitz, MD, CHU de la Timone
- Studiestol: Jean-Louis Legoux, MD, Hopital Haut Leveque
- Studiestol: Pascal Hammel, MD, PhD, Hopital Beaujon
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Sykdommer i det endokrine systemet
- Neoplasmer i fordøyelsessystemet
- Neoplasmer i endokrine kjertel
- Pankreassykdommer
- Neoplasmer i bukspyttkjertelen
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Enzymhemmere
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Beskyttende agenter
- Mikronæringsstoffer
- Vitaminer
- Kalsiumregulerende hormoner og midler
- Motgift
- Vitamin B kompleks
- Gemcitabin
- Fluorouracil
- Leucovorin
- Kalsium
- Levoleucovorin
Andre studie-ID-numre
- CDR0000453841
- FFCD-0301
- EU-20543
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Bukspyttkjertelkreft
-
Tianjin Medical University Cancer Institute and...Har ikke rekruttert ennåPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Cedars-Sinai Medical CenterRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaForente stater
-
Radboud University Medical CenterDutch Cancer SocietyRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaNederland
-
Thomas Jefferson UniversityUkjentBukspyttkjertelfistel | Distal pankreatektomikomplikasjoner | Falciform Patch Pancreatic Closure | Fibrinlim bukspyttkjertellukkingForente stater
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... og andre samarbeidspartnereRekrutteringBukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaStorbritannia
-
Chinese PLA General HospitalRekrutteringNeoplasmer i bukspyttkjertelen | Bukspyttkjertelkreft | Bukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaKina
-
Andrei IagaruIkke lenger tilgjengeligKarsinoide svulster | Islet Cell (Pancreatic NET) | Andre nevroendokrine svulsterForente stater
Kliniske studier på fluorouracil
-
Sun Yat-sen UniversityZhejiang Cancer Hospital; Fudan University; Peking University Cancer Hospital... og andre samarbeidspartnereUkjentNasofaryngealt karsinomKina
-
Sun Yat-sen UniversityUkjent
-
CStone PharmaceuticalsAktiv, ikke rekrutterendeIkke-opererbart lokalt avansert, tilbakevendende eller metastatisk esofageal plateepitelkarsinomKina
-
The Netherlands Cancer InstituteFullført
-
Actavis Inc.FullførtAktinisk keratoseForente stater
-
The Netherlands Cancer InstituteFullført
-
Hokkaido Gastrointestinal Cancer Study GroupHokkaido University HospitalFullført
-
Hong Kong Nasopharyngeal Cancer Study Group LimitedThe Hong Kong Anti-Cancer Society; hong Kong Cancer FundFullført
-
Boston UniversityRekrutteringOverfladisk basalcellekarsinom | Plateepitelkarsinom in situForente stater
-
Medical Research CouncilFullførtBlærekreft | Overgangscellekreft i nyrebekkenet og urinlederen | Kreft i urinrøretCanada, Storbritannia, Norge, New Zealand, Nederland, Sør-Afrika, Brasil, Finland